NEOLEAD

K011564 · Neotech Products, Inc. · DRX · Jan 3, 2002 · Cardiovascular

Device Facts

Record IDK011564
Device NameNEOLEAD
ApplicantNeotech Products, Inc.
Product CodeDRX · Cardiovascular
Decision DateJan 3, 2002
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 870.2360
Device ClassClass 2
AttributesPediatric

Intended Use

The NeoLead Hydrocolloid/ Hydrogel electrode is intended to be used for resting ECG monitoring on neonatal and pediatric patients in a hospital setting.

Device Story

NeoLead is a disposable, self-adhesive sensor for neonatal and pediatric patients. It captures cardiac electrical impulses non-invasively via skin contact and transmits them to an external monitor for display of electrographic patterns. The device utilizes a pectin-based hydrogel for conductivity and a hydrocolloid adhesive for skin-friendly attachment, following Neonatal Nurses National Association guidelines. It is intended for use in hospital settings to facilitate cardiac monitoring.

Clinical Evidence

Bench testing only. The device met AAMI performance standards for disposable ECG electrodes, including AC impedance, DC offset voltage, combined offset instability and internal noise, defibrillation overload recovery, and bias current tolerance.

Technological Characteristics

Disposable, self-adhesive ECG sensor. Materials: pectin-based hydrogel (conductive) and hydrocolloid (adhesive). Complies with AAMI standards for disposable ECG electrodes (AC impedance, DC offset, noise, defibrillation recovery, bias current).

Indications for Use

Indicated for resting ECG monitoring in neonatal and pediatric patients in hospital settings.

Regulatory Classification

Identification

An electrocardiograph electrode is the electrical conductor which is applied to the surface of the body to transmit the electrical signal at the body surface to a processor that produces an electrocardiogram or vectorcardiogram.

Special Controls

*Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9. The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Electrocardiograph Electrodes.” See § 870.1(e) for availability information of guidance documents.

Predicate Devices

Reference Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ KO 11554 p/2 JAN 0 3 2002 ## 510 K SUMMARY # DESCRIPTION OF DEVICE The Neolead is a self-adhesive, disposeable sensor, which receives electrical impulses from the body in a non-invasive manner. These impulses are then transmitted to a monitor, which displays the electrographic patterns of cardiac activity. Hydrogel is the pectin based conductive material between the skin and the sensor. Hydrocolloid is the pectin based adhesive. ## INTENDED USE OF THE DEVICE Neoleads are designed as a desposeable, self-adhesive sensor to be placed on the skin of the newborn and pediatric patient in order to gather, transmit and record cardiac electrical activity. ### TECHNICAL CHARACTERISTICS The Neolead is equivalent to legally marketed electrodes in the marketplace now. The addition of the hydrocolloid as the adhesive is based on the recommendations of the Neonatal Nurses National Association guidelines as well as a long history of its skin friendly properties. # SUBSTANTIAL EQUIVLENCE The Neolead is substantially equivalent to the following predicated electrodes > Kittvcat-Kendall-LTP Neotrode-ConMe Corp Klear-Trace-CAS Medical Systems, Inc SilveReez-Clinimark H/P -HewlettPackard The Hydrocolloid adhesive used with the Neolead is substantially equivalent to the Hydrocolloid in other Neotech predicated devices. | NeoBar | NeoSmile | |-----------|----------| | NeoBridge | NeoHold | | NeoShades | NeoBond | {1}------------------------------------------------ K011564 p. 2/2 ### 510 K SUMMARY CONTINUED # ELECTRICAL PERFORMANCE SUMMARY The Neoleads meet the basic performance standards (3.2.2.1 AC Impedance, 3.2.2.2 DC Offset Voltage, 3.2.2.3 Combined Offset Instability and Internal Noise, 3.2.2.4 Defibrillation Overload Recovery, 3.2.2.5 Bias Current Tolerance) of the AAMI for Disposable ECG Electrodes. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized caduceus symbol, which features a staff entwined with a serpent. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 JAN 0 3 2002 Arnold M. Heyman, M.D. Neotech Products, Inc. 9135-F Alabama Ave. Chatsworth, CA 91311 Re: K011564 Trade Name: NeoLead Regulation Number: 21 CFR 870.2360 Regulation Name: Electrocardiograph Electrode Regulatory Class: Class II (two) Product Code: DRX Dated: Not Dated Received: October 5, 2001 Dear Dr. Heyman: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {3}------------------------------------------------ Page 2 - Arnold M. Heyman, M.D Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours, Donlin Telle Bram D. Zuckerman, M.D. Acting Director Division of Cardiovascular and Respiratory Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ # Statement of Indication for Use The NeoLead Hydrocolloid/ Hydrogel electrode is intended to be used for resting ECG monitoring on neonatal and pediatric patients in a hospital setting. Division of Cardiovascular & Respiratory Devices 510(k) Number K011564 Prescription Use (Per 21 CFR 801.109)
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...